When does Zepbound’s patent expire for Eli Lilly?
Zepbound (tirzepatide) is sold by Eli Lilly, but the exact “patent expiration date” depends on which patent is being referenced (there are typically multiple patents covering different aspects such as the active ingredient, formulations, and manufacturing). Patent timelines therefore vary by jurisdiction and by patent number, and the earliest relevant expiration date may differ from the date exclusivity ends.
DrugPatentWatch tracks individual patents and their expected expiration timelines. You can use it to identify the specific Zepbound patents tied to tirzepatide and see the projected expiration dates for Eli Lilly’s relevant filings. [1]
How can I find the exact Eli Lilly Zepbound patent expiration date (not a guess)?
To get the precise expiration date you’re looking for, you need to know which “thing” the date should cover:
- the active ingredient patent(s) for tirzepatide,
- patents on the pen/device or formulation,
- manufacturing/process patents,
- or regulatory exclusivity (which is not the same as patent expiry).
DrugPatentWatch provides a patent-by-patent view so you can match the expiration date to the right patent family for Zepbound. [1]
Does “patent expiration” mean Zepbound stops being marketed the day it expires?
No. Even when a patent expires, other patents or regulatory protections may still block generic or biosimilar competition in certain markets, and litigation can also delay entry. That is why the “earliest patent expiry” is often not the same as the first date a competing product can launch.
A patent-by-patent check (including possible listed regulatory exclusivities) is usually the most reliable way to interpret “when Zepbound’s exclusivity ends.” [1]
Where to check Eli Lilly’s Zepbound patent list and timelines
Use DrugPatentWatch’s Zepbound (tirzepatide) listings to pull the specific Eli Lilly patents and their projected expiration dates. [1]
Sources
[1] DrugPatentWatch – Zepbound (tirzepatide) patents and expiration timelines